New data in diabetic obese/overweight patients look positive for lorcaserin
This article was originally published in Scrip
Executive Summary
In the wake of the recent US complete response letter for their weight loss product Lorqess (lorcaserin), Arena Pharmaceuticals and Eisai have released positive top-line results from a Phase III clinical trial with the product in obese and overweight patients with type 2 diabetes.